---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-26-000036"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2026-07-30T20:08:09+00:00"
generated_at: "2026-07-30T20:09:13.758458+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q2 revenue up 44% to $335M; raises 2026 guidance to $1.34-1.36B

## Summary
- Q2 revenue $335.0M (+44% YoY); Oncology $219.1M (+38%), Screening $52.9M (+258%).
- Net loss $120.1M ($0.90/share); non-GAAP net loss $56.2M ($0.42/share).
- 2026 revenue guidance raised to $1.34-1.36B (prior $1.30-1.32B), growth 36-38%.
- Screening revenue guidance raised to $218-230M; Shield volume 270k-285k tests.
- FDA approved Guardant360 Liquid CDx; Shield included in ACS guidelines, UnitedHealth coverage.

## SEC filing metadata
- accession: 0001576280-26-000036
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2026-07-30T20:08:09+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/0001576280-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/gh-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-26-000036
- JSON: https://secwatch.observer/filing/0001576280-26-000036.json
- Plain text: https://secwatch.observer/filing/0001576280-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.